Interventions for fatigue in peripheral neuropathy by White, CM et al.
Interventions for fatigue in peripheral neuropathy (Review)
White CM, van Doorn PA, Garssen MPJ, Stockley RC
This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library
2014, Issue 12
http://www.thecochranelibrary.com
Interventions for fatigue in peripheral neuropathy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
6BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
15ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
19DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
21AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
21ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
34DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
34ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
34WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
35CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
35DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
35SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
36DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
36INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iInterventions for fatigue in peripheral neuropathy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Interventions for fatigue in peripheral neuropathy
Claire M White1, Pieter A van Doorn2 , Marcel PJ Garssen3, Rachel C Stockley4
1Health&Social Care Research, Faculty of Life Sciences&Medicine, King’s College London, London,UK. 2Department ofNeurology,
Erasmus University Medical Center, Rotterdam, Netherlands. 3Neurology, Jeroen Bosch Hospital And Erasmus Medical Centre, s’-
Hertogenbosch, Netherlands. 4Physiotherapy, Faculty of Health, Psychology & Social Care, Elizabeth Gaskell Campus, Manchester,
UK
Contact address: Claire MWhite, Health & Social Care Research, Faculty of Life Sciences &Medicine, King’s College London, Room
3.22, Shepherd’s House, Guy’s Campus, London, SE1 1UL, UK. Claire.white@kcl.ac.uk.
Editorial group: Cochrane Neuromuscular Disease Group.
Publication status and date: Edited (no change to conclusions), published in Issue 12, 2014.
Review content assessed as up-to-date: 5 November 2013.
Citation: WhiteCM, vanDoorn PA, GarssenMPJ, Stockley RC. Interventions for fatigue in peripheral neuropathy.Cochrane Database
of Systematic Reviews 2014, Issue 12. Art. No.: CD008146. DOI: 10.1002/14651858.CD008146.pub2.
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Persistent feelings of fatigue (or subjective fatigue), which may be experienced in the absence of physiological factors, affect many people
with peripheral neuropathy. A variety of interventions for subjective fatigue are available, but little is known about their efficacy or the
likelihood of any adverse effects for people with peripheral neuropathy.
Objectives
To assess the effects of drugs and physical, psychological or behavioural interventions for fatigue in adults or children with peripheral
neuropathy.
Search methods
On 5 November 2013, we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE,
EMBASE, CINAHL Plus, LILACS and AMED. We also searched reference lists of all studies identified for inclusion and relevant
reviews, and contacted the authors of included studies and known experts in the field to identify additional published or unpublished
data. We also searched trials registries for ongoing studies.
Selection criteria
We considered for inclusion randomised controlled trials (RCTs) and quasi-RCTs comparing any form of intervention for fatigue
management in adults with peripheral neuropathy with placebo, no intervention or an alternative form of intervention for fatigue.
Interventions considered included drugs, pacing and grading of physical activity, general or specific exercise, compensatory strategies
such as orthotics, relaxation, counselling, cognitive and educational strategies.
Data collection and analysis
Two review authors independently assessed risk of bias and extracted study data.We contacted study authors for additional information.
We collected information on adverse events from the included trials.
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Main results
The review includes three trials, which were all at low risk of bias, involving 530 people with peripheral neuropathy. The effects
of amantadine from one randomised, double-blind, placebo-controlled, cross-over trial comparing amantadine with placebo for the
treatment of fatigue in 80 people withGuillain-Barré syndrome (GBS)were uncertain for the proportion of people achieving a favourable
outcome six weeks post-intervention (odds ratio (OR) 0.56 (95% confidence interval (CI) 0.22 to 1.35, N = 74, P = 0.16). We assessed
the quality of this evidence as low. Two parallel-group randomised double-blind, placebo-controlled trials comparing the effects of two
doses of ascorbic acid with placebo for reducing fatigue in adults with Charcot-Marie-Tooth disease type 1A (CMT1A) showed that the
effects of ascorbic acid at either dose are probably small (standardised mean difference (SMD) -0.12 (95% CI -0.32 to 0.08, n = 404,
P = 0.25)) for change in fatigue after 12 to 24 months (moderate quality evidence). Neither ascorbic acid study measured fatigue at
four to 12 weeks, which was our primary outcome measure. No serious adverse events were reported with amantadine. Serious adverse
events were reported in the trials of ascorbic acid. However,risk of serious adverse events was similar with ascorbic acid and placebo.
Authors’ conclusions
One small imprecise study in people with GBS showed uncertain effects of amantadine on fatigue. In two studies in people with
CMT1A there is moderate-quality evidence that ascorbic acid has little meaningful benefit on fatigue. Information about adverse effects
was limited, although both treatments appear to be well tolerated and safe in these conditions.
There was no evidence available from RCTs to evaluate the effect of other drugs or other interventions for fatigue in either GBS,
CMT1A or other causes of peripheral neuropathy. The cost effectiveness of different interventions should also be considered in future
randomised clinical trials.
P L A I N L A N G U A G E S U M M A R Y
Treatments for fatigue in peripheral neuropathy
Review question
To assess the effects of treatments for fatigue in people with peripheral neuropathy.
Background
Peripheral neuropathy is damage to the nerves outside the brain and spinal cord. Many people with peripheral neuropathy have feelings
of severe tiredness (fatigue) that are not necessarily related to physical problems such as muscle weakness. Evidence in other long-term
illnesses where fatigue is a problem suggests that medicines and other forms of treatment may help. The aim of this review was to assess
the effect of drugs and other treatments, such as general or specific exercise, orthotics (devices such as braces), relaxation, counselling
and cognitive, behavioural and educational strategies on feelings of fatigue in people with peripheral neuropathy.
Study characteristics
From a wide search, we identified three RCTs that met our selection criteria. The trials involved a total of 530 adults with peripheral
neuropathy. Treatments were ascorbic acid (vitamin C) in people with Charcot-Marie-Tooth disease in two trials, and amantadine
in Guillain-Barré syndrome in the third. Charcot-Marie-Tooth disease is an inherited nerve disease and Guillain-Barré syndrome is
a condition where there is inflammation of the peripheral nerves. We chose measures of fatigue at four to 12 weeks as our preferred
measure of the effects of treatment. The amantadine trial but not the ascorbic acid trials provided data at this time point; the ascorbic
acid trials provided data more than 12 months after the start of the intervention.
Key results and quality of the evidence
There was insufficient evidence to determine the effects of amantadine when compared with an inactive treatment (placebo) for fatigue.
and there were no major unwanted effects. We found evidence that ascorbic acid probably has little meaningful benefit for fatigue.
No major unwanted effects were identified, but the trials were small. We assessed the quality of this evidence as moderate because the
results were imprecise, which means they do not rule out the possibility that the drugs could have an effect. We found no evidence
from RCTs on other medicines or treatments for fatigue in peripheral neuropathy.
There is insufficient evidence to determine the effect of amantadine for fatigue in GBS and ascorbic acid for fatigue in CMT1A. More
high-quality studies are needed to provide evidence on which to base management of feelings of fatigue in peripheral neuropathy. The
cost effectiveness of different interventions should also be considered in future RCTs.
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The evidence in this review is current to November 2013.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Amantadine versus placebo for fatigue in Guillain-Barré syndrome
Patient or population: people with fatigue in Guillain-Barré syndrome
Settings:
Intervention: amantadine versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Amantadine
Reduction in fatigue of
at least 1-point on the
Fatigue Severity Scale
between 4 to 12 weeks
after commencement of
intervention
Fatigue Severity Scale
(FSS) from 1 to 7 (higher
score is worse)
Follow-up: mean 12
weeks
257 per 1000 162 per 1000
(71 to 318)
OR 0.56
(0.22 to 1.35)
74
(1 cross-over study)
⊕⊕©©
low1
-
Change in fatigue 12 or
more weeks after com-
mencement of interven-
tion (not measured)
- - - - - -
Change in activity limi-
tation 12 or more weeks
after commencement of
intervention (not mea-
sured)
- - - - - -
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Change in participation
12 or more weeks after
commencement of inter-
vention using the
Rotterdam Hand-
icap Scale. Scale from: 0
to 36.
Follow-up: mean 12
weeks
The mean change in par-
ticipation 12 or more
weeks after commence-
ment of intervention using
the control group was
0.34 points
The mean change in par-
ticipation 12 or more
weeks after commence-
ment of intervention us-
ing the intervention group
was
0.31 higher
(0.09 lower to 0.72
higher)
74
(1 cross-over study)
⊕⊕©©
low1
-
Health related quality of
life after 12 or more
weeks or more after
commencement of inter-
vention (not reported)
- - - - - EHQ and SF-36measured
but data not fully reported
Serious adverse events
Follow-up: mean 12
weeks
See comment See comment Not estimable 80
(1 cross-over study)
See comment 0 participants had seri-
ous adverse events in this
study
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; OR: odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Evidence downgraded two levels due to imprecision (small sample size and wide CI that crosses the line of no effect).
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B A C K G R O U N D
Description of the condition
Peripheral neuropathies collectively affect about 2.4% of the pop-
ulation and may be either genetic or acquired, and either acute
or chronic in nature (Martyn 1998). The pathological process af-
fects peripheral nerves, resulting in neurological damage to either
the axon (ie, degeneration of the central nerve fibre), the myelin
(ie, demyelination or destruction of the insulating sheath of the
nerve), or a combination of both. Recovery may be by remyelina-
tion, through which improvements in function can be rapid, and
in some people there is almost complete recovery. However, re-
generation of damaged axons usually takes many months or years
and recovery, if present, may be incomplete (Tamura 2007).
Common symptoms of peripheral neuropathy include numbness,
diminished or altered sensation (pins and needles), muscle weak-
ness, and autonomic dysfunction. People may also experience fa-
tigue, pain, psychological dysfunction and poor social adjustment
(Lennon 1993; Pfeiffer 2001). Even when neurological function
improves, residual symptoms often persist and fatigue is frequently
an ongoing problem (Merkies 1999).
The experience of fatigue (or subjective fatigue) has been described
as a “an overwhelming sense of tiredness, lack of energy and feeling
of exhaustion” that is “not relieved by rest” and is a common sequel
of chronic conditions (Bleijenberg 2003; Karlsen 1999; Krupp
2003). Physiological fatigue, or “the loss of voluntary force-pro-
ducing capacity during exercise” (Bigland-Ritchie 1978) can con-
tribute to subjective fatigue, but people can experience subjective
fatigue in the absence of physiological factors and physiological
fatigue does not necessarily result in subjective fatigue.
Physical factors such as residual muscle weakness mean that peo-
ple with peripheral neuropathy have to work harder during ev-
eryday activities than healthy individuals, which will feel more
of an effort. Axonal degeneration prevents nerve impulses from
being conducted along the peripheral nerve and demyelination
can lead to conduction block that can be exacerbated by muscle
activity (Cappelen-Smith 2000), leading to fatigue (Kaji 2000).
Although there is no direct problem with the muscles themselves,
it has been shown that people with peripheral neuropathy may be
unable to voluntarily activate their muscles fully, possibly because
of dysfunction within the central nervous system (Garssen 2007;
Schillings 2003). This form of physiological fatigue is known
as central fatigue and could possibly be due to reduced drive
from nerve cells in the brain (cortical neurons) or to the effect
of alterations in the number of surviving peripheral nerve axons
and an increase in the number of muscle fibres they innervate
(Martinez-Figuerora 1977; Sanders 1996). In addition, psycho-
logical factors such as lack of motivation or low mood can also af-
fect voluntary activation of muscles (Gandevia 2001; Kent-Braun
1993). Fear of precipitating fatiguemay also contribute and lead to
an avoidance of physical activity and physical deconditioning, thus
further exacerbating fatigue (Moss-Morris 2005). Environmental
factors may also precipitate fatigue, since many people with pe-
ripheral neuropathies have to utilise compensatory strategies such
as orthoses or walking aids as a result of deformities or sensory
deficits. Therefore, the experience of fatigue may be clearly related
to known underlying factors or, more commonly, be only partly
explained by these. Finally, measurement of the level of fatigue is
difficult both because the subjective experience of fatigue varies
between individuals and because measures of different types of
fatigue are numerous.
Description of the intervention
The evidence about the efficacy of interventions for fatigue in
peripheral neuropathy and other chronic conditions is limited and
unclear. Interventions aim to address physical, environmental and
psychological factors contributing to fatigue, and include drugs,
pacing and grading of physical activity, general or specific exercise,
orthotics, relaxation, counselling, cognitive behavioural strategies
and others.
How the intervention might work
The presumedmode of action of drug interventions such as aman-
tadine for generalised fatigue is unknown (Pucci 2009); one ran-
domised controlled trial (RCT) showed no effect in inflamma-
tory peripheral neuropathy (Garssen 2006). It is likely that factors
contributing to subjective fatigue in individuals with peripheral
neuropathy must be clearly understood in order to target interven-
tions effectively. For example, where fatigue is due to weakness,
strengthening exercise may be beneficial, but where altered mood
or well-being is a factor then drug, cognitive or behavioural inter-
ventions may be more relevant. It is likely that multidimensional
interventions that address individuals’ self perception and health
beliefs combined with strategies to increase levels of physical activ-
ity or participation in regular exercise or both may also be helpful.
Why it is important to do this review
Fatigue is a frequent and often severe problem that affects everyday
activities and quality of life for people with peripheral neuropa-
thy. Although there have been some RCTs of drug and non-drug
interventions for fatigue in peripheral neuropathy, we know of no
systematic review.
O B J E C T I V E S
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To assess the effects of drugs and physical, psychological or be-
havioural interventions for fatigue in adults or children with pe-
ripheral neuropathy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised controlled trials (RCTs) or quasi-
RCTs of any drug or non-drug intervention to treat fatigue as-
sociated with peripheral neuropathy, compared with placebo, no
treatment or other drug or non-drug interventions for fatigue.
Quasi-RCTs are those in which randomisation was intended but
they use methodology that may be biased, such as alternation, or
use of case record numbers or date of birth.
Types of participants
We considered for inclusion in the review all trials in which partic-
ipants (adults or children) had fatigue associated with a diagnosis
of peripheral polyneuropathy, including sensory, motor and com-
bined sensory and motor neuropathies. We did not consider trials
including mostly people with focal disease such as local entrap-
ment neuropathies with pain as the primary presenting feature (for
example, cervical radiculopathy, carpal tunnel syndrome, brachial
plexus neuritis, etc), and poliomyelitis. We accepted the diagnosis
of peripheral neuropathy offered by the study authors, provided
that it stipulated the presence of clinical impairment characteristic
of peripheral neuropathy. We did not include diagnoses depen-
dent on symptoms suggestive of neuropathy alone or neurophys-
iological abnormalities in the absence of clinical signs.
Types of interventions
We considered trials including any form of intervention for fatigue
management, such as drugs, pacing and grading of physical activ-
ity, general or specific exercise, compensatory strategies such as or-
thotics, relaxation, counselling, cognitive and educational strate-
gies and others, compared with either placebo, no intervention or
an alternative form of intervention for fatigue.
Types of outcome measures
Primary outcomes
Our primary outcome was fatigue severity and symptoms as mea-
sured by any validated scale evaluated at least four weeks and less
than 12 weeks after commencement of the intervention. Where
studies used more than one scale, we used the preferred ranking of
commonly-used scales shown below to identify the scale to be used
in the primary outcome analysis. Instruments that we considered
appropriate included: Fatigue Severity Scale (FSS) (Krupp 1989),
Chalder Fatigue Scale (Chalder 1993), Fatigue Impact Scale or
daily-FIS (D-FIS) (Fisk 1994; Fisk 2002), Visual Analogue Scale
of Fatigue (VAS-F) (Lee 1991), and Piper Fatigue Scale (PFS)
(Piper 1998).
Secondary outcomes
1. Fatigue after 12 or more weeks.
2. Activity limitations after 12 or more weeks.
3. Participation restrictions after 12 or more weeks.
4. Health-related quality of life after 12 or more weeks.
5. Adverse events: any adverse events, adverse events which lead
to discontinuation of treatment and serious adverse events, which
are those which are fatal, life-threatening, or require prolonged
hospitalisation.
Search methods for identification of studies
Electronic searches
On 5 November 2013, we searched the Cochrane Neuromuscular
DiseaseGroup SpecializedRegister, theCochraneCentral Register
of Controlled Trials (CENTRAL) (2013, Issue 10), MEDLINE
(January 1966 to October 2013), EMBASE (January 1980 to Oc-
tober 2013), LILACS (January 1982 to October 2013), CINAHL
Plus (January 1937 to October 2013) and AMED (January 1985
to October 2013). The detailed search strategies are in the ap-
pendices: Appendix 1 (MEDLINE), Appendix 2 (EMBASE), Ap-
pendix 3 (CINAHL Plus), Appendix 4 (CENTRAL), Appendix 5
(AMED), Appendix 6 (LILACS) and Appendix 7 (the Cochrane
Neuromuscular Disease Group Specialized Register).
On 12 June 2014 we searched the Current Controlled
Trials register (www.controlled-trials.com), ClinicalTrials.gov (
www.clinicaltrials.gov) and theWHOInternational Clinical Trials
Registry Platform (ICTRP) (www.who.int/ictrp/en/), using the
search terms ’fatigue’ and ’peripheral neuropathy’.
Searching other resources
We reviewed the bibliographies of the randomised trials identi-
fied, contacted the trial authors and known experts in the field,
and approached pharmaceutical companies to identify additional
published or unpublished data.
Data collection and analysis
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Selection of studies
Two review authors (CMW, RCS) independently examined the ti-
tles and abstracts identified by the search. There were no language
restrictions. We obtained English language translations where ap-
propriate. We retrieved all trials that were relevant and reviewed
full-text publications. We examined retrieved publications against
the selection criteria and we resolved any disagreement by con-
sensus.We did not have to resort to arbitration by a third author
(MPG). If trials had had a heterogenous sample of disorders, we
would have only included them if data from participants with
peripheral neuropathy could be isolated or if at least 75% of the
participants had peripheral neuropathy.
Data extraction and management
For each retrieved publication, two review authors (CW and
RCS) independently extracted the relevant data using standardised
forms. We resolved any disagreements by discussion. We gathered
data on:
• eligibility criteria;
• interventions;
• details of participants;
• assignment to groups;
• outcome measures;
• time at which outcomes are measured;
• funding;
• declarations of interest;
• sample size; and
• statistical analysis.
Assessment of risk of bias in included studies
Two out of three review authors (CW, RS andMG) independently
assessed all included studies for risk of bias. We graded the items
according to the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011a) and presented our assessments in a
’Risk of bias’ table. We assessed trials for random sequence gen-
eration, allocation concealment, blinding (participants, personnel
and outcome assessors), incomplete outcome data, selective out-
come reporting and other potential sources of bias.
We then made a judgement on each of these criteria relating to
the risk of bias, of ’low risk of bias’, ’high risk of bias’ or ’unclear
risk of bias’.
Measures of treatment effect
Continuous data
For studies using the same outcome measures, we summarised
continuous data using mean differences (MDs), sometimes called
’weighted mean differences’, with a corresponding 95% confi-
dence interval (CI). When different studies measured the same
outcome in different ways we analysed results using standardised
mean differences (SMDs) with a 95% CI.
Dichotomous data
For studies using similar outcomes with dichotomous data we
calculated a pooled estimate of the risk ratio (RR), with a 95% CI.
Unit of analysis issues
Where there were multiple intervention groups within a trial,
we made pairwise comparisons of similar interventions or active
components versus no treatment, placebo, or another interven-
tion. We planned to analyse cross-over trials with continuous out-
come measures using generalised inverse variance analysis (GIV)
(DerSimonian 1986), where the estimated difference in the mean
treatment effects and their standard errors were available for pool-
ing with equivalent results from parallel-group studies. If this in-
formation had not been available then we would have pooled data
from the first phase only, where possible, with parallel design stud-
ies. For cross-over studies with dichotomous outcomes we would
have pooled results using odds ratios (ORs) and confidence inter-
vals from paired analyses where available (Elbourne 2002). Only
one cross-over trial was included for any comparison, so no deci-
sions about pooling data were necessary. We would have reported
trials with unique designs or outcomes without a meta-analysis.
We excluded studies that were not RCTs from the analyses but we
comment on them in the Discussion.
Dealing with missing data
For all outcomes, where continuous data were presented as mean
change with 95% CIs, the standard deviations (SDs) were cal-
culated for input into analyses and forest plots assuming a nor-
mal distribution due to a moderate sample size, using the equa-
tion SD = SQRT of number of participants X (upper limit of CI
to lower limit of CI) / 3.92. as recommended in Section 7.7.3.2
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011b).Where overall disability sum score (ODSS) data
were presented as median and interquartile ranges, we did not in-
put any data for analysis. Where participant dropout led to miss-
ing data we contacted trial authors if an intention-to-treat analysis
had not been performed. We also contacted authors where there
were missing data for review outcomes, and additional data were
provided for the secondary outcome of participation in one study
(Garssen 2006).
Assessment of heterogeneity
We undertook meta-analysis when studies investigated similar in-
terventions, used similar outcome measures and included groups
of participants who were clinically homogeneous. Where studies
were heterogeneous for some outcomes we undertook a narrative
review.
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If studies were similar in intervention, outcome measurement and
participants, we assessed possible inconsistency across studies us-
ing the I² statistic (Higgins 2003; Higgins 2011a). If studies had
been heterogeneous (Q statistic = 0.1 and I² statistic of 25% or
greater), the review authors would have considered conducting
subgroup analysis only. If we had considered the primary studies
to be heterogeneous even within subgroups, we would have un-
dertaken a narrative approach rather than a meta-analysis.
Assessment of reporting biases
We did not use funnel plots to investigate associations between
effect size and study precision in terms of sample size, because
of the small number of studies included in the review. If we had
included funnel plots, we would have explored the relationships
observed to investigate differences between studies with large and
small samples, or systematic biases, such as publication bias.
Data synthesis
For studies with a similar type of intervention or a similar active
component, we performed ameta-analysis to calculate a treatment
effect across trials with a fixed-effect model, as heterogeneity was
not demonstrated. Dichotomous outcome results were available
from only one study so we did not present pooled RRs. Where it
was not possible to perform a meta-analysis we provided descrip-
tive summaries of the results from each trial.
’Summary of findings’ table
We created ’Summary of findings’ tables using the following out-
comes:
1. Fatigue severity and symptoms between four and 12 weeks
after commencement of the intervention.
2. Fatigue after 12 or more weeks.
3. Activity limitations after 12 or more weeks.
4. Participation restrictions after 12 or more weeks.
5. Health-related quality of life after 12 or more weeks.
6. Serious adverse events.
We used the five GRADE considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias) to assess the quality of a body of evidence (studies that
contribute data) for the prespecified outcomes. We used meth-
ods and recommendations described in Chapters 11 and 12 of
the Cochrane Handbook for Systematic Reviews of Interventions
(Schünemann 2011a; Schünemann 2011b).We used GRADEpro
software (GRADEpro 2008). We explained decisions to down- or
up-grade the quality of studies using footnotes and we made com-
ments to aid reader’s understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
Insufficient data available. See Appendix 8 for methods planned
but not implemented.
Sensitivity analysis
Insufficient data available. See Appendix 8 for methods planned
but not implemented.
This review has a protocol (White 2009). We listed any deviations
from the protocol in Differences between protocol and review.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies for details.
The electronic and manual searches identified a total of 1386 ti-
tles and abstracts. After removing duplicates and excluding ab-
stracts where studies were clearly not eligible for inclusion, only
six full publications, four protocols and two abstracts were rele-
vant to the review. After reading the full text of the six published
articles we excluded three: two were not randomised controlled
trials (RCTs) (Carter 2006; Enderlin 2008) and one was an RCT
of ascorbic acid for children with CMT1A in which fatigue was
not an outcome (Burns 2009). We included one abstract of con-
ference proceedings, regarding an RCT of a new low-dose com-
bination of three already approved drugs for CMT1A, as an on-
going trial, as the analyses are ongoing (Attarian 2013). We will
include this study in future updates of this review if appropriate.
Two of the other five ongoing or unpublished studies were RCTs
of ascorbic acid in CMT1, and we contacted the authors for fur-
ther information (NCT00484510; Verhamme 2009). However,
in these ongoing studies, fatigue was not included as an outcome
and we excluded them. One randomised trial of coenzyme Q10
for CMT (NCT00541164), with changes in weakness, fatigue
and pain as the primary outcome, is completed but appears to be
unpublished. NCT02121678 is not yet recruiting, but will study
resistance training for chronic inflammatory demyelinating neu-
ropathy (CIDP) with the fatigue severity scale (FSS) as a planned
secondary outcome. We identified one study, Ramdharry 2011,
from an abstract in the Cochrane Neuromuscular Disease Group
Specialized Register. The study appears to be ongoing and the au-
thors provided no data when contacted. We will include it if eli-
gible once the full publication is available. See Characteristics of
ongoing studies.
The study selection process therefore resulted in only three trials
finally meeting the criteria for inclusion (Garssen 2006; Micallef
2009; Pareyson 2011).
Study design and participants
We include three studies evaluating the efficacy of two drugs for
fatigue in two different populations (Garssen 2006;Micallef 2009;
Pareyson 2011).
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The first study (Garssen 2006) was a randomised, double-blind,
placebo-controlled, cross-over trial of amantadine for severe fa-
tigue in 80 neurologically well-recovered participants who had had
Guillain-Barré syndrome (GBS). Randomisation was in blocks of
six with half the study participants receiving amantadine first and
the remainder receiving placebo first. Interventions were followed
by a two-week washout period. Assessment of outcomes occurred
on six occasions: 1: at baseline, 2: following two weeks of no in-
tervention, 3: after six weeks of intervention 1, 4: after a two-week
washout period, 5: after six weeks of intervention 2, and finally
6: after a further two-week washout period. Three randomised
participants were withdrawn from the study in the pre-cross-over
phase. One participant was in the placebo group and withdrew be-
cause of concern over potential side effects of amantadine when she
became pregnant. The two other participants were in the amanta-
dine treatment group; one withdrew because of hospital admission
with acute cholangitis and the second participant developed severe
complaints of dizziness. A further three participants were excluded
from the analysis due to incorrect completion of the FSS. There-
fore, 74 participants with GBS were included in the reporting of
outcomes. All participants had been diagnosed with GBS between
six months and 15 years previously and had no apparent changes
in GBS disability score for the three months prior to entering the
study. All could walk at least 10 metres with or without a walking
aid (GBS disability score < 3).
The two remaining studies (Micallef 2009; Pareyson 2011) were
parallel-group, randomised, double-blind, placebo-controlled tri-
als of the effect of ascorbic acid in a total of 450 adults with Char-
cot-Marie-Tooth disease type 1A (CMT1A). In one, two doses
(either 1 g or 3 g daily) of ascorbic acid or placebo were used in
the treatment of 179 participants (Micallef 2009). Confirmation
of diagnosis was by clinical examination and genotyping with du-
plication in 17p11.2 and at least one motor sign or symptom (gait
disorder, distal amyotrophy, foot deformation or distal weakness).
Block randomisation into three groups with matching for study
site and sex was followed by 12 months of treatment with either
1 g or 3 g of ascorbic acid or placebo; outcomes were assessed at
baseline and after 12 months of intervention. A total of 16 partici-
pants withdrew from the study after randomisation due to adverse
events (six), withdrawal of consent (six), loss to follow-up (two),
non-compliance (one) or missing baseline data (one).
Therefore, 163 participants completed the study but analysis was
of all 179 participants, on an intention-to-treat basis.
In the second multicentre study (Pareyson 2011), the efficacy of
chronic administration, for 24 months, of either 1.5 g/day ascor-
bic acid or placebo in the treatment of 271 participants (eligible
for analysis) with Charcot-Marie-Tooth disease 1A was evaluated.
Participants had a clinical diagnosis of Charcot-Marie-Tooth dis-
ease 1A with genetic confirmation of 17p11.2-p12 duplication
and a CMT neuropathy score of between 1 (excluding the elec-
trophysiological component) and 35 (including the electrophys-
iological component). Block randomisation of 277 participants
into groups of four stratified by disease severity and centre was
followed by 24 months of treatment with either ascorbic acid or
placebo, and outcomes were assessed at six-monthly intervals from
commencement of intervention until 24 months. Six participants
did not receive the allocated intervention after randomisation, and
are dropped from the denominators. A total of 22 participants
withdrew from the intervention after commencement. Reasons for
withdrawal were adverse events (13), withdrawal of consent (six),
moved away from study area (two) or for personal reasons (one).
Whilst the primary study outcome was based on all randomised
patients who received at least one dose of the study drug using im-
putation for missing data the secondary analyses were conducted
without imputation of missing data.
Interventions
The study of amantadine in Guillain-Barré syndrome was a cross-
over trial in which amantadine was compared with placebo at a
dose of one tablet (100 mg) daily for one week followed by two
tablets daily for the remaining five weeks of each intervention
period. A washout period of two weeks was incorporated before
the participants shifted to the other treatment arm (amantadine
or placebo) (Garssen 2006).
The studies of ascorbic acid in Charcot-Marie-Tooth disease 1A
were a parallel-group study comparing 1 g or 3 g of ascorbic acid
in a single administration of three capsules with three placebo
capsules for 12 months (Micallef 2009) and a parallel-group study
comparing 1.5 g of ascorbic acid in two daily doses with placebo
tablets for 24 months (Pareyson 2011).
Outcomes
In participants with severe fatigue due to Guillain-Barré syndrome
(defined as Fatigue Severity Scale (FSS) 5.0 or more; FSS range 1
to 7), Garssen 2006 used a reduction of at least one point on the
FSS as a primary outcome measure of fatigue. Outcomes for FSS
were reported for both phases of the cross-over study. Secondary
outcomemeasures in themajor domains of the International Clas-
sification of Functioning, Disability and Health (ICF) were: for
structure and function, anxiety and depression using the Hospi-
tal Anxiety and Depression Scale (HADS); for activity, impact of
fatigue using the Fatigue Impact Scale (FIS); and for participa-
tion, Rotterdam Handicap Scale (RHS), quality of life using the
Medical Outcomes Short Form-36 (SF-36) Health Survey and the
Euroquol Health Questionnaire (EQHQ); and adverse events.
In the studies of ascorbic acid in participants with Charcot-Marie-
Tooth disease 1A, the primary outcome was CMT neuropathy
score (CMTNS). Fatigue was assessed as a secondary outcome
using the change in Visual Analogue Scale - Fatigue (VAS-F),
either 12 months (Micallef 2009) or 24 months (Pareyson 2011)
after commencement of the intervention. Secondary outcomes of
activity limitation using theOverall Disability Sum Score (ODSS)
(Micallef 2009) or Overall Neuropathy Limitations Scale (ONLS)
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(Pareyson 2011), 10 metre walk test (10MWT) Pareyson 2011
and 9 hole peg test (9HPT) (Pareyson 2011) were reported, as
well as measures of participation and quality of life using the SF-
36 and adverse events in both studies.
Risk of bias in included studies
See Characteristics of included studies for details and Figure 1.
Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study. Key: green (+) = low risk of bias; yellow (?) = unclear risk of bias; red (-) = high risk
of bias.
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Garssen 2006 conducted block randomisation in blocks of six,
although allocation was concealed from researchers; we therefore
considered the study to be at low risk of bias for these criteria. The
trial was a double-blind, placebo-controlled study, with 80 partici-
pants initially enrolled. Although the final analysis was based on 74
participants as six were withdrawn, there was adequate reporting
of the loss to follow-up. Sample size was calculated using estimates
of proportion from unpublished data obtained from a pilot study,
indicating that 36 participants per group were required for 90%
power at a two-sided 5% alpha, so that with 77 participants com-
pleting the trial it was sufficiently powered to detect a difference.
The washout period of two weeks between cross-over intervention
phases seems sufficient to avoid a carry-over effect of amantadine,
and is comparable with other randomised controlled cross-over
designs of efficacy for amantadine in other populations (Cohen
1989; Pucci 2009;Rosenberg 1988). The authors reported data for
mean (SD) improvement in FSS scores for both amantadine and
placebo treatment in both the amantadine-placebo (0.46 (1.29), P
= 0.078; 95%CI -0.92 to 0.05) and placebo-amantadine sequence
(0.08 (1.44), P = 0.28; 95% CI -1.24 to 0.44) groups and t-test
analysis for period effects and carry-over effects were not signifi-
cant. There was some evidence of selective reporting of secondary
outcomes, as only P values were reported. Overall we considered
the study to be at low risk of bias.
In Micallef 2009, sequence generation was conducted by an inde-
pendent contract research organisation who were also responsible
for concealed allocation of randomisation into blocks of 12 that
were stratified for sex and study site (three sites). The trial was dou-
ble-blind with the administration of visually identical hard gelatin
capsules for all groups. Analysis was on an intention-to-treat basis
with 179 participants randomised and analysed despite 15 with-
drawals prior to follow-up (four from the placebo group, eight
from the 1 g ascorbic acid group and three from the 3 g ascorbic
acid group); one participant from the placebo group had missing
baseline data for the study’s primary outcome. All study outcomes
were adequately reported.Whilst authors stated that the data were
analysed on an intention-to-treat basis there was no indication of
how the investigators dealt with the missing data from 16 partici-
pants. Our overall summary assessment was that the study was at
low risk of bias.
In the third study (Pareyson 2011), an independent randomisa-
tion unit was responsible for sequence generation and group allo-
cation stratified for disease severity and treatment centre in blocks
of four. This, combined with the use of placebo tablets of identical
appearance, taste and smell, resulted in blinding of participants,
researchers and treating physicians. Six participants randomised to
the intervention (four participants) and placebo (two participants)
groups withdrew consent before receiving the allocated interven-
tion and were excluded from analysis. Although the investigators
recorded outcome data at six-monthly intervals for 24 months,
the authors stated that their main analysis would be at 24 months,
and reported the primary outcome at only 12 and 24 months and
the secondary outcomes only at 24months. Overall we considered
this study to be at low risk of bias.
Effects of interventions
See:Summary of findings for themain comparisonAmantadine
versus placebo for fatigue in Guillain-Barré syndrome; Summary
of findings 2Ascorbic acid versus placebo for fatigue in peripheral
neuropathy
Amantadine versus placebo in Guillain-Barré
syndrome
Effect estimates, where data were available, were obtained from
a single trial, so we downgraded the quality of evidence for all
outcomes for this reason (Summary of findings for the main
comparison).
Primary outcome
Fatigue between four and 12 weeks after commencement of
intervention
Garssen 2006 assessed baseline measures at visit 1 and at visit 2,
prior to randomisation. In the 74 participants for whom full out-
come data were reported, there was evidence of a reduction in fa-
tigue between these baseline visits, which was stated by the authors
to approach significance (P = 0.05 Wilcoxon signed rank test), al-
though complete group data were not presented. The magnitude
of fatigue reduction before the start of any intervention was such
that although themedian FSS score for the 74 participants was 5.9
at visit 2, seven (9%) of the participants had an FSS score lower
than the inclusion criterion of FSS 5 for severe fatigue.
Thirty-six participants received amantadine followed by placebo
and 38 received placebo followed by amantadine. Favourable out-
come reporting was available for both phases of each treatment se-
quence, representing evaluation of the primary outcome six weeks
after the commencement of intervention. Results were presented
as the mean difference (MD) in reduction in FSS scores between
amantadine and placebo, and as an odds ratio (OR) of a favourable
outcome (defined as a reduction of more than 1 in FSS score). The
overall MD in FSS score between amantadine and placebo phases
was -0.45 (95% CI -0.94 to 0.04; t = -1.80; df = 73; P = 0.076).
When the participants responding favourably to one treatment
only in both the group receiving amantadine followed by placebo
(amantadine-placebo group) and those receiving placebo followed
by amantadine (placebo-amantadine group) were combined, the
number with a more favourable outcome following amantadine
was 9 of 25 (36%) participants with an OR of 0.56 (95% CI 0.22
to 1.35, P = 0.16) using the McNemar test.
Secondary outcomes
All stated secondary outcomes inGarssen 2006 were only reported
at six weeks after commencement of the intervention and therefore
not at the stated secondary outcome point of 12 or more weeks
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after commencement of intervention for this review. In addition
full data for the study secondary outcomes were not available, as
only P values were provided (Garssen 2006). The data indicated
that there was no significant improvement in: fatigue impact us-
ing the fatigue impact scale (FIS) (P = 0.77); participation using
the Rotterdam Handicap Scale (RHS) (P = 0.14) and Euroquol
Health Questionnaire (EQHQ) (P = 0.21) at six weeks. The au-
thors reported that quality of life using the SF-36 demonstrated a
significant improvement in physical role functioning (P = 0.008)
and mental health perception (P = 0.008), although only in the
placebo group (Garssen 2006). We contacted the authors for fur-
ther information about secondary outcomes; the RHS scores for
participation at six weeks from the original data were provided
by the trial author (Garssen 2006). The data were analysed us-
ing a paired two-sample t-test and showed that the MD between
the change in participation with placebo versus the change with
amantadine between four to 12 weeks after commencement of
intervention was 0.31 (95% CI -0.09 to 0.72, P = 0.13) (Table 1).
(Summary of findings for the main comparison).
Fatigue after 12 or more weeks
Not reported at this time point.
Activity limitations after 12 or more weeks
Not reported at this time point.
Participation restrictions after 12 or more weeks
Not reported at this time point.
Health-related quality of life (HRQoL) after 12 or more weeks
Not reported at this time point.
Adverse events
Reported in Garssen 2006.
No serious adverse events were reported. However, mild, transient
adverse effectswere reported in 32out of 80 (40%)participants: 22
participants during amantadine treatment and 10 during placebo
treatment. Adverse effects included anticholinergic complaints (six
participants: three in each treatment group), gastrointestinal com-
plaints (10 participants: seven in placebo group and three in aman-
tadine group), sleep complaints (10 participants: nine in amanta-
dine group and one in placebo group) and other less frequent side
effects (headache, feelings of nervousness and vivid dreams). No
side effects were reported to have affected trial participation.
Ascorbic acid versus placebo in Charcot-Marie-Tooth
disease
Primary outcome
Fatigue between four and 12 weeks after commencement of
intervention
Neither study evaluating ascorbic acid for Charcot-Marie-Tooth
disease 1A reported change in fatigue within the time scale of the
primary outcome for this review (Micallef 2009; Pareyson 2011).
Secondary outcomes
Data for secondary outcomes were reported at 12 months after
commencement of the intervention in Micallef 2009 and at 24
months after commencement of the intervention in Pareyson
2011. Where two different doses of ascorbic acid were used in
Micallef 2009, we combined data from both intervention arms,
including participants receiving a higher dose (3 g ascorbic acid)
and those receiving a lower dose (1 g ascorbic acid) in comparisons
for all outcomes.
Fatigue after more than 12 weeks
Reported in Micallef 2009 and Pareyson 2011.
Both studies assessed fatigue using change inVisual Analogue Scale
for fatigue (VAS-F). Fatigue was assessed at 12-month follow-up
using a 0 to 100 VAS for fatigue inMicallef 2009 and at 24-month
follow-up using a 0 to 10 VAS for fatigue in Pareyson 2011. The
pooled estimate of effect of the change in fatigue more than 12
weeks after commencement of the intervention was standardised
mean difference (SMD) -0.12 (95% CI -0.32 to 0.08, P = 0.25;
N = 404; I² = 0%) (see Analysis 1.1; Figure 2).
Figure 2. Forest plot of comparison: 2 Ascorbic acid versus placebo, outcome: 2.1 Change in fatigue > 12
weeks after commencement of intervention at 12 months [VAS 0 - 100).
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Activity limitations after 12 or more weeks
Reported in Micallef 2009 and Pareyson 2011.
Activity limitationwas assessed using theODSS at 12months after
commencement of intervention in Micallef 2009 and the Over-
all Neuropathy Limitations Scale (ONLS) 24 months after com-
mencement of intervention in Pareyson 2011. Pooling of data in
a meta-analysis was not possible since data for ordinal scale scores
were presented as medians plus interquartile ranges (IQRs), and
there was no indication of whether the data were skewed. How-
ever, the authors reported that there was no significant difference
(P = 0.22) inmedian change in activity limitation between placebo
and 1 g or 3 g doses of ascorbic acid at 12 months in Micallef
2009, and no significant difference (P = 0.99) in median change
in activity limitation between placebo and 1.5 g dose of ascorbic
acid in Pareyson 2011.
In addition, further measures of activity limitation were included
in both studies. The 10MWTwasmeasured in bothMicallef 2009
and Pareyson 2011 (at 12 months and 24 months, respectively)
and the pooled estimate of effect for change in time taken to
walk 10 metres more than 12 weeks after commencement of the
intervention was MD -0.39 (95% CI -1.04 to 0.26, P = 0.24; N =
406; I² = 0%) (Analysis 1.2; Figure 3). In addition the 9HPT was
measured in Pareyson 2011 at 24 months and showed that there
was no significant effect of ascorbic acid (MD -0.74, 95% CI -
1.60 to 0.12, P = 0.09; N = 224) (Analysis 1.3).
Figure 3. Forest plot of comparison: 1 Ascorbic acid versus placebo, outcome: 1.2 Change in 10 m timed
walk > 12 weeks after commencement of the intervention (measured at 12 to 24 months) [seconds].
Participation restrictions after 12 or more weeks
Not reported in Micallef 2009 or Pareyson 2011.
Health-related quality of life (HRQoL) after 12 or more
weeks
Reported as an outcome and assessed using the SF-36 at 12months
after commencement of the intervention in Micallef 2009 and
24 months after commencement of the intervention in Pareyson
2011. We calculated a pooled estimate of the change in physical
functioning, as measured by the Physical Component Score (PCS)
in Micallef 2009 and the Physical Function Scale (PFS) of the SF-
36 in Pareyson 2011. Using data from 400 participants, the SMD
was 0.08 (95% CI -0.12 to 0.28) favouring placebo (see Figure
4, Analysis 1.4). There was no significant statistical heterogeneity,
despite the difference in duration of follow-up (I² = 0%, P = 0.67).
Figure 4. Forest plot of comparison: 2 Ascorbic acid versus placebo, outcome: 2.4 Change in physical
function score of SF-36.
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Micallef 2009 reported HRQoL assessed by the Mental Compo-
nent Score of the SF-36 and for this too there was no significant
difference (P = 0.77) between either dose of ascorbic acid versus
placebo or in a combined analysis, between both doses of ascorbic
acid versus placebo, 12 months after the start of treatment (Anal-
ysis 1.5).
Adverse events
Reported in Micallef 2009 and Pareyson 2011.
In Micallef 2009, 896 adverse events were documented in 158
(89%) participants (55 of 62 participants in the placebo group
(89%); 47 of 56 participants in the 1 g ascorbic acid group (89%),
and 56 of 61 participants in the 3 g ascorbic acid group (92%)), of
which only 24 were serious adverse events. Serious adverse events
were recorded in 22 participants (eight in the placebo group, seven
in the 1 g ascorbic acid group and seven in the 3 g ascorbic acid
group). Researchers deemed the majority of events (70%) not to
be related to treatment and 208 (25%) to have a possible relation
to treatment, of which only 12 (11 listed in the report) were se-
vere: upper abdominal pain (2), dyspepsia (2), headache (1), in-
somnia (1), muscle spasm (1), musculoskeletal stiffness (1), rash
(1), rhinitis (1) and sleep disturbance (1). Six participants (one in
the placebo group, four in the 1 g ascorbic acid group and one in
the 3 g ascorbic acid group) gave adverse events (cystitis, myalgia,
depression, colitis and insomnia) as reasons for withdrawal from
the study.
In Pareyson 2011, 21 serious adverse events were documented
in 20 participants (eight events in seven of 138 participants in
the ascorbic acid group and 13 events in 13 of 133 participants
in the placebo group). Researchers considered all but one event,
where a woman in the placebo group was admitted to hospital
due to anaemia, as unrelated to the intervention. Thirteen partic-
ipants experiencing adverse events were lost to follow-up (six in
the placebo group and seven in the ascorbic acid group), and eight
participants (six in the placebo group and two in the ascorbic acid
group) ceased treatment as a result of a serious adverse event. Five
of these eight continued with follow-up and three (two receiv-
ing placebo and one receiving ascorbic acid) withdrew from the
study. Adverse events in those who discontinued the interventions
included gastralgia, abdominal cramps or diarrhoea (9), surgery
(4), renal colic (1), pregnancy (3), rectal bleeding (1), saccharine
intolerance (1) and gum disease (1). The pooled risk ratio (RR)
for serious adverse events in studies of ascorbic acid for CMT1A
was 0.70 (95% CI 0.39 to 1.27, P = 0.24; N = 450; I² = 0%)
(see Analysis 1.6, Figure 5), indicating no significant difference in
serious adverse events between ascorbic acid and placebo.
Figure 5. Forest plot of comparison: 2 Ascorbic acid versus placebo, outcome: 2.6 Adverse events.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Ascorbic acid versus placebo for fatigue in peripheral neuropathy
Patient or population: people with fatigue in peripheral neuropathy
Settings:
Intervention: ascorbic acid versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Ascorbic acid
Reduction in fatigue of
at least 1 point on the
Fatigue Severity Scale
(FSS) between 4 to 12
weeks after commence-
ment of intervention (not
measured)
- - - - - -
Change in fatigue 12 or
more weeks after com-
mencement of interven-
tion
Visual Analogue Scale
(VAS) of fatigue
Follow-up: mean 12-24
months
- The mean change in fa-
tigue 12 or more weeks
after commencement of
intervention in the inter-
vention groups was
0.12 standard deviations
lower
(0.32 lower to 0.08
higher)
- 404
(2 studies)
⊕⊕⊕©
moderate1
-
Change in activity limita-
tion (ODSS/ONLS) 12 or
more weeks after com-
mencement of interven-
tion
See comment See comment Not estimable 406
(2 studies)
- Data available were not
suitable for meta-analysis
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Overall Neuropathy Lim-
itations Scale or Over-
all Disability Sum Score.
Scale from: 0 to 12.
Follow-up: 12-24 months
Change in 10 metre
timed walk 12 or more
weeks after commence-
ment of intervention
Time taken to walk 10
metres in seconds
Follow-up: 12-24 months
The mean changes in 10
metre timed walk 12 or
more weeks after com-
mencement of interven-
tion in the control groups
werea decrease of 0.40
seconds and an increase
of 0.76 seconds2
The mean change in 10
metre timed walk 12 or
more weeks after com-
mencement of interven-
tion in the intervention
groups was a decrease
of
0.39 seconds (1.04
faster to 0.26 slower)
406
(2 studies)
⊕⊕⊕©
moderate1
-
Change in speed of com-
pletion of 9-hole peg test
(in seconds) 12 or more
weeks after commence-
ment of intervention
Time (in seconds) taken
to complete 9-hole peg
test
Follow-up: mean 24
months
The mean change in
speed of completion of
the 9-hole peg test was
an increase of 0.85 sec-
onds in the control group
The mean change in
speed of completion of
the 9-hole peg test was
a decrease of 0.74 sec-
onds
(1.60 faster to 0.12
slower)
Not estimable 224
(1 study)
⊕⊕⊕©
moderate1
-
Health-related quality of
life 12 or more weeks
after commencement of
the intervention
Change in SF-36 physi-
cal function score
SF-36 Physical Function-
ing Scale and Physical
Component Score
Follow-up: 12-24 months
- The mean health-related
quality of life 12 or more
weeks after commence-
ment of the intervention
(change in SF-36 physi-
cal function score) in the
intervention groups was
0.08 standard deviations
higher
(0.12 lower to 0.28
higher)
- 400
(2 studies)
⊕⊕⊕©
moderate1
-
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Change in participation
12 or more weeks after
commencement of inter-
vention (not measured)
- - - - - -
Health-related quality of
life 12 or more weeks
after commencement of
the intervention Change
in mental function score
of SF-36
SF-36 Mental Component
Score
Follow-up: mean 12
months
The mean change in
health-related quality of
life 12 or more weeks
after commencement of
the intervention (change
in mental function score
of SF-36) in the control
group was 1.2 points
The mean health-related
quality of life 12 or more
weeks after commence-
ment of the intervention
(change in mental func-
tion score of SF-36) in the
intervention groups was
0.9 higher
(2.65 lower to 4.45
higher)
- 123
(1 study)
⊕⊕⊕©
moderate1
-
Serious adverse events
Follow-up: 12 months
108 per 1000 76 per 1000
(42 to 137)
RR 0.70
(0.39 to 1.27)
450
(2 studies)
⊕⊕⊕⊕
moderate1
-
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Only one or two studies included.
2 Assumed control group risks are the control group values in the two trials.
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D I S C U S S I O N
Summary of main results
Our search identified three randomised controlled trials (RCTs)
thatmet the inclusion criteria. The trials evaluated the effect of two
different drugs on fatigue in two different populations of people
with peripheral neuropathy. Two studies examined the effect of
different doses of ascorbic acid in Charcot-Marie-Tooth disease
1A, and therefore no combined analysis was possible.
The first study (Garssen 2006) was a block-randomised, double-
blind, placebo-controlled, cross-over study of amantadine for se-
vere fatigue in 74 neurologically stable participants at least six
months after Guillain-Barré syndrome. We judged the risk of bias
of the trial to be low. The study reported a moderate reduction
in fatigue severity scale (FSS) score for participants treated with
amantadine but the confidence interval was wide and study size
relatively small, suggesting that the study may have been under-
powered to detect a difference; we therefore graded the quality of
the evidence as low. These data indicate that larger studies might
improve the power to detect a reduction in risk of fatigue with
amantadine. Nevertheless, the mean difference (MD) did not ex-
ceed the minimal clinically important difference for change in
FSS scores estimated for people with systemic lupus erythemato-
sus (MD 0.6; 95% CI 0.3 to 0.9), indicating that it is likely that
there is no effect of amantadine compared with placebo in the
treatment of severe fatigue (see Summary of findings for the main
comparison). A significant decrease in fatigue was noted between
two pre-treatment baseline visits two weeks apart. Since the par-
ticipants were considered to be neurologically stable, this suggests
that increased attention to people with fatigue due to Guillain-
Barré syndrome may improve symptoms of fatigue.
The two studies evaluating ascorbic acid for Charcot-Marie-Tooth
(CMT)disease 1Awere block-randomised, double-blind, placebo-
controlled trials of different doses of ascorbic acid for the treatment
of Charcot-Marie-Tooth disease 1A (Micallef 2009; Pareyson
2011). The risk of bias for Micallef 2009 was low, despite the fact
that there was no report of howmissing data were dealt with in the
intention-to-treat analysis. All other aspects of risk of bias assess-
ment were adequate. The main findings were that whilst ascorbic
acid was well-tolerated and safe for adults with Charcot-Marie-
Tooth disease 1A over a period of 12 months, there were no signif-
icant differences in effect across all outcomes, including fatigue,
between placebo, 1 g or 3 g of ascorbic acid (see Summary of
findings 2). There was a low risk of bias in the remaining study
(Pareyson 2011), and the main findings were that ascorbic acid
supplementation at a dose of 1.5 g per day for 24 months was
well tolerated but there was no significant effect on neuropathy or
secondary outcomes compared with placebo.
Overall completeness and applicability of
evidence
Only three RCTs (Garssen 2006; Micallef 2009; Pareyson 2011)
were eligible for inclusion in the review. One was of amantadine
for severe fatigue in Guillain-Barré syndrome and the others were
of three different doses of ascorbic acid for people with Charcot-
Marie-Tooth disease 1A. RCTs evaluating the effect of other in-
terventions for fatigue, such as other drugs; pacing and grading of
physical activity; general or specific exercise; compensatory strate-
gies such as orthotics; relaxation; counselling; cognitive and edu-
cational strategies; and interventions for fatigue that form part of a
multidimensional programme, or trials of interventions for other
causes of peripheral neuropathy, were not available. None of the
included studies considered the cost effectiveness of interventions
for fatigue in peripheral neuropathy
Quality of the evidence
The overall risk of bias in the included trials (Garssen 2006;
Micallef 2009; Pareyson 2011) was low.
Garssen 2006 reported a double-blind, placebo-controlled study,
where, despite a block randomisation procedure affecting bias in
sequence generation and incomplete reporting of secondary out-
comes, there was effective allocation concealment and P values for
secondary outcomes were available. Reporting of data for fatigue
during both phases of the trial indicates that there was no signifi-
cant carry-over effect. We therefore judged the overall risk of bias
to be low.
Micallef 2009 reported a block-randomised, double-blind,
placebo-controlled study, where all assessed aspects of risk of bias
were adequate except for the lack of reporting of howmissing data
were dealt with for an intention-to-treat analysis. We therefore
judged the overall risk of bias to be low.
Pareyson 2011 reported a block-randomised, double-blind,
placebo-controlled study with a low risk of bias overall.
Since only one trial of amantadine for the treatment of fatigue in
Guillain-Barré syndrome (Garssen 2006) and two trials of ascorbic
acid for treatment of Charcot-Marie-Tooth disease 1A (Micallef
2009; Pareyson 2011) are included in the review, it is not possible
to address the review objectives for drug or other interventions.
The Garssen 2006 study was relatively small (74 participants) and
the results actually suggest that theremay be an effect, but the study
is under-powered. We downgraded the evidence from this study
to low because of its imprecision (Summary of findings for the
main comparison). Larger studies including those with different
doses and frequency of administration of amantadine are desirable
before a definite conclusion about the effect of amantadine to treat
fatigue in peripheral neuropathy and in particular in Guillain-
Barré syndrome can be given.
The studies of ascorbic acid for Charcot-Marie-Tooth disease 1A
were larger, and evaluated the effect of three different doses of
ascorbic acid in Charcot-Marie-Tooth disease 1A (Micallef 2009;
Pareyson 2011). The lack of reporting of how missing data were
dealt with in Micallef 2009 means that it is difficult to assess
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whether the risk of bias is likely to have favoured the control or
ascorbic acid treatment groups in this study . Nevertheless, the
low risk of bias associated with the final study (Pareyson 2011)
and the fact that it has similar findings to Micallef 2009 meant
that we did not downgrade the evidence because of trial design or
conduct, but did downgrade it because of the lack of reporting of
howmissing data was dealt with inMicallef 2009. Thismeans that
there is moderate-quality evidence suggesting that ascorbic acid
has no benefit in the treatment of fatigue in CMT (See Summary
of findings 2).
The primary outcome of fatigue was evaluated using the FSS or
VAS for fatigue in the included studies. The FSS is based on clas-
sical test theory (CTT), where scales may include items not rel-
evant for particular clinical populations, and scale sum scores as-
sume equal weighting of items where this has not necessarily been
demonstrated. This potentially introduces bias into the assessment
of the underlying outcome of interest. However, evidence in the
current review was not downgraded due to directness based on
outcomes used, since the effect of indirectness is not currently
known. Nevertheless, clinicians and researchers are moving to-
wards linearly weighted scales based onmodern scientific methods
such as Rasch models or item response theory (IRT) for evalu-
ation of outcomes in clinical populations. The FSS has recently
been fully evaluated andmodified using the Rasch unidimensional
measurement model (RUMM2020) and is recommended for use
in immune-mediated neuropathy (van Nes 2009). Its relevance
for other peripheral neuropathies remains to be evaluated.
Potential biases in the review process
Two review authors were also investigators in an included trial
(Garssen 2006), but neither was involved in assessing the risk of
bias in this study.
We contacted study authors where there were missing data, and
these was provided by Garssen 2006 for one secondary outcome.
We also contacted authors of published abstracts with limited re-
porting of data for further information, but they either did not
reply or declined to, stating their intention to publish a full report
of the study in the future as a reason.
This systematic review used an adequate search strategy to avoid
missing any RCTs on treatments for fatigue in peripheral neu-
ropathy. There were no language restrictions in our searches, and
whilst a limitation of the review is that we did not initially plan in
our protocol to search clinical trials registers, this additional search
was subsequently conducted; this difference between the protocol
and review is flagged up below.
The criteria for types of participants for including studies accepted
the diagnosis of peripheral neuropathy offered by the authors, pro-
vided that it stipulated the presence of clinical impairment char-
acteristic of peripheral neuropathy. We considered only sensory,
motor or combined sensory and motor peripheral neuropathies,
and excluded studies of participants with focal entrapment neu-
ropathies with pain as the primary presenting feature, and with po-
liomyelitis. There is therefore a small possibility that misdiagnosis
of participants may have affected study inclusion, and that stud-
ies with mixed populations of participants that include both sen-
sory, motor and combined sensory motor neuropathies as well as
painful entrapment neuropathies or poliomyelitis were excluded.
This could be a potential source of selection bias in the review.
Agreements and disagreements with other
studies or reviews
There are currently no other systematic reviews of interventions
for fatigue in peripheral neuropathy available, despite many treat-
ments for fatigue including: drugs, pacing and grading of phys-
ical activity, general or specific exercise, compensatory strategies
such as orthotics, relaxation, counselling, cognitive and educa-
tional strategies, either alone or as part of a multidimensional pro-
gramme.
Systematic reviews of interventions for fatigue
in other conditions
In the absence of evidence from reviews or high-quality RCTs in
peripheral neuropathy it may be helpful to consider the effect of
interventions for fatigue in other conditions, including chronic
fatigue syndrome (CFS), fibromyalgia, multiple sclerosis and can-
cer-related fatigue. The high incidence of anxiety and depression
in functional somatic syndromes such as fibromyalgia and CFS
(Henningsen 2003) and the specific pathophysiological features
of multiple sclerosis and cancer-related fatigue mean that recom-
mendations from systematic reviews should be considered with
caution. In all cases we included only evidence from Cochrane
systematic reviews.
Drugs for fatigue
The evidence from Cochrane systematic reviews of drugs in the
treatment of fatigue in other conditions was of varying quality.
A systematic review of serotonin and noradrenaline reuptake in-
hibitors (SNRIs) for fibromyalgia indicated that they only pro-
vide a small improvement in fatigue (1.7% improvement) over
placebo (Hauser 2013). In reviews of amantadine or carnitine for
fatigue inmultiple sclerosis, the poor quality of the available RCTs
meant that no conclusion regarding their efficacy could be drawn
(Pucci 2009; Tejani 2012). Finally, whilst the updated system-
atic review of drug therapy for the management of cancer-related
fatigue provides evidence that psychostimulant trials may give a
clinically meaningful improvement in cancer-related fatigue, new
safety data indicate that the drugs are associated with increased
adverse outcomes and they can no longer be recommended in the
treatment of cancer-related fatigue (Minton 2010).
Non-drug interventions for fatigue
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We reviewed the evidence from recent Cochrane systematic re-
views of non-drug interventions for fatigue in other conditions,
which suggests that exercise (Edmonds 2004) and cognitive be-
havioural therapy (CBT) (Price 2008) for fatigue in CFS are both
better than usual care, with the evidence for CBT being more
extensive and robust than for exercise. In a review of exercise for
treating fibromyalgia syndrome, there is very limited evidence that
aerobic-only exercise is likely to have no effect on fatigue in in-
dividuals with fibromyalgia (Busch 2007). A systematic review of
cognitive behavioural therapies for fibromyalgia concludes that
there was only a 5.8% (95% CI 0.05 to 11.3) effect on fatigue
(Bernardy 2013). A systematic review of exercise for management
of cancer-related fatigue concluded that aerobic exercise is benefi-
cial (Cramp 2012).
Evidence from individual studies of interventions for
fatigue in neuropathy
One article describing an uncontrolled case series of people with
Charcot-Marie-Tooth disease 1A treatedwithmodafinil for fatigue
reported that all four participants had less fatigue within at least 10
days of commencing modafinil treatment (Carter 2006). The case
study design means that this report has substantial risk of bias but
may suggest that modafinil is a potentially useful drug for fatigue
in people with Charcot-Marie-Tooth disease 1A, and merits well-
designed trials.
The wide variety of causes and consequences in peripheral neu-
ropathy, combined with a relatively low prevalence of individual
conditions means that controlled trials of non-drug interventions
have been limited. In addition, despite the substantial prevalence
of fatigue in people with peripheral neuropathy (Merkies 1999),
subjective fatigue is not routinely evaluated in RCTs and other
study designs of such interventions. However, one cohort study
(Garssen2004) andone case-control study (Graham 2007) of exer-
cise for people with Guillain-Barré syndrome and chronic inflam-
matory demyelinating polyradiculoneuropathy (CIDP) reported
significant reductions in fatigue after 12 weeks of either supervised
aerobic cycling (Garssen 2004) or unsupervised community-based
exercise (Graham 2007). Whilst these studies are subject to very
high risks of bias due to their design, they may suggest that RCTs
of exercise for people with fatigue due to peripheral neuropathy
should be conducted.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence from randomised controlled trials of the efficacy
of interventions for fatigue in peripheral neuropathy is limited.
One small study comparing amantadine with placebo for fatigue
in people with Guillain-Barré syndrome was not sufficiently pow-
ered to determine the effects on fatigue in this population. There
was moderate quality evidence that the effects of ascorbic acid on
fatigue in people with Charcot-Marie-Tooth disease 1A are small.
Information about adverse effectswas limited, although both treat-
ments appeared to be well tolerated in these conditions.
There was no evidence available from randomised controlled tri-
als to evaluate the effect of other interventions for fatigue in ei-
ther Guillain-Barré syndrome, Charcot-Marie-Tooth disease 1A
or other causes of peripheral neuropathy.
Implications for research
The dearth of evidence from high-quality randomised controlled
trials on the effects of interventions for fatigue in peripheral neu-
ropathy indicates that treatments for this condition warrant fur-
ther research. Trials in relevant patient populations should have
adequate sample size, appropriate randomised controlled designs
and clinically relevant standardised and responsive measures of fa-
tigue as an outcome.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Garssen 2006
Methods Randomised, double-blind, placebo-controlled, cross-over trial
Duration 18 weeks:
• 2 weeks pre-treatment period
• 6 weeks first intervention period
• 2 weeks washout
• 6 weeks second intervention period
• 2 weeks washout
Block randomisation in blocks of 6
Participants Identified from Dutch Guillain-Barré syndrome databank or the Dutch Neuromuscular
Disorders Patients Association (Vereniging Spierziekten Nederland)
80 (40 female and 40 male) neurologically stable participants with GBS (no apparent
change in GBS disability score within 3 months of the start of the study) with severe
fatigue (mean FSS score of ≥ 5) who were over 18 years old, with a GBS disability score
< 3 (able to walk at least 10 metres with or without aid)
Exclusion criteria: presence of severe fatigue prior to onset of GBS, comorbidity with
conditions that might cause fatigue, receiving medication that may induce fatigue, score
of > 10 on the depression subscale of the HADS, contraindications for treatment with
amantadine including pregnancy and breastfeeding, renal dysfunction, and allergy to
amantadine
Interventions Amantadine 100 mg once daily for 1 week then twice daily for 5 weeks (n = 40 allocated,
36 in analysis) or placebo (n = 40 allocated, 38 in analysis), followed after washout by
the opposite intervention
Outcomes 1. Reduction in severe fatigue by at least 1 point on the FSS
2. Impact of fatigue - FIS
3. Mood - HADS
4. Participation/handicap - RHS
5. Quality of life - SF-36 and EQHQ
Funding This studywas supported by a grant from theDutchOrganization for Scientific Research,
NWO (grant no. 940-38-009)
Declarations of interest None stated
Notes 7 people were excluded prior to randomisation for insufficient fatigue (< 5 on FSS)
Ethical approval was gained in May 2000 but no information on the duration of the
study is reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Garssen 2006 (Continued)
Random sequence generation (selection
bias)
Low risk Allocation sequence generated by block
randomisation (block size of 6)
Allocation concealment (selection bias) Low risk Allocation sequence list sent to pharmacy
department and consecutive people at out-
patient department assigned a number
from 1 to 80 in sequence of entering the
study
Blinding (performance bias and detection
bias)
All outcomes
Low risk Placebo-controlled trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analysis based on 74 participants, as 6
withdrawn: 3 fromfirst interventionperiod
(1 from the placebo group and 2 from the
amantadine group) and a further 3 partic-
ipants withdrawn due to inadequate com-
pletion of FSS
Selective reporting (reporting bias) High risk Only P values reported for 4 secondary out-
comes: fatigue impact,mood, participation
limitation, and quality of life
Other bias Low risk Washout period similar to studies of aman-
tadine in other populations. Carry-over ef-
fect of 2-week washout period tested by au-
thors and no significant effect reported
Micallef 2009
Methods Block-randomised, double-blind, placebo-controlled, multicentre trial
Duration: 12 months
Participants Participants were recruited from 3 hospital sites in France
195 patients were initially screened and 179 (110 women and 69 men) with a clinical
diagnosis of CMT1A confirmed by genotyping with duplication in 17p11.2 were sub-
sequently randomised prior to intervention
Participants were aged between 18 and 70 years of age and had to have at least one
motor symptom or sign (gait disorder, distal amyotrophy, foot deformation or muscle
weakness). People with any cause of neuropathy other than CMT1A and other medical
conditions: kidney stones, hypersensitivity or intolerance to ascorbic acid or lactose, un-
corrected oxalosis, cardiovascular disease, poliomyelitis or radiotherapy, those for whom
ascorbic acid supplementation was contra-indicated, women of childbearing age who
were pregnant, breastfeeding or not using adequate contraception, were excluded
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Micallef 2009 (Continued)
Interventions Participants were randomised in a 1:1:1 ratio to ascorbic acid 1 g, (n = 56), ascorbic acid 3
g (n = 61) or placebo containing lactose (n = 62), all given as a single daily administration
of 3 hard gelatine capsules for 12 months
Outcomes Primary outcome: Charcot-Marie-Tooth neuropathy score (CMTNS) at 12months after
commencement of intervention
Secondary outcomes
1. Muscle strength - QMT
2. Gait velocity - timed 10 metre walk
3. Activity - ODSS
4. Quality of life - Medical Outcomes SF-36
5. VAS for fatigue, pain, cramps and difficulty walking
6. CGI-S
Funding No indication of funding given
Declarations of interest One study author (MF) is one of the inventors of the patent for ascorbic acid for the
treatment of CMT1A licensed to Murigenetics. Two of the study authors (MF and OB)
are scientific advisers to Murigenetics and are 15% shareholders in the company
Notes Participants were recruited from Sept 2005 to September 2007
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation stratified to site and
sex for subgroup analyses with sequence
generation using an independent contract
research organisation
Allocation concealment (selection bias) Low risk Randomisation list sent to an indepen-
dent research organisation for preparation
of ascorbic acid and placebo capsule (iden-
tical hard gelatine capsules)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Ascorbic acid and placebo formulated from
hard gelatine capsules (identical in weight,
appearance and taste). Placebo contained
lactose
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analyses were on an intention-to-treat ba-
sis. Reporting of dropouts (total 16) was
effective: 6 withdrew (1 in placebo, 4 in
1g ascorbic acid and 1 in 3 g ascorbic acid
group) due to adverse events (cystitis, myal-
gia, gastralgia, depression, colitis and in-
somnia), 2 were lost to follow up (1 in
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Micallef 2009 (Continued)
placebo and 1 in 3 g ascorbic acid group)
, 6 withdrew consent (1 in placebo, 4 in 1
g ascorbic acid and 1 in 3 g ascorbic acid)
, 1 was non-compliant with treatment in
the placebo group and 1 placebo partici-
pant was missing a baseline CMTNS score
Selective reporting (reporting bias) Low risk All stated primary and secondary outcomes
were fully reported
Other bias Unclear risk Intention-to-treat analysis meant sufficient
sample size for adequate power. No indica-
tion of howmissing datawere dealt with for
intention-to-treat analyses. Therefore diffi-
cult to determine risk of bias due tomethod
Pareyson 2011
Methods Parallel, randomised, double-blind, placebo-controlled, multicentre trial
Duration 24 months
Participants Recruited from 8 Italian hospitals and 1 UK hospital between March 2006 and Sept
2007
354 patients screened for eligibility and 277 eligible patients subsequently randomly
assigned to intervention. Six participants did not subsequently receive the allocated in-
tervention and were excluded, leaving intervention 138 (78 women and 60 men) and
placebo 133 (85 women and 48 men). All participants had a clinical and genetic diagno-
sis of CMT1A. Participants were aged between 18 and 70 years and had a CMTNS of
between 1 (excluding the electrophysiology component) and 35 (including the electro-
physiology component). Exclusion criteria: any cause of neuropathy other thanCMT1A;
other clinically significant neurological or systemic disease; limb surgery in the 6 months
before screening or planned before the final assessment; pregnancy, breastfeeding or
planning to become pregnant during the study; receipt of extra-dietary ascorbic acid
supplementation in the 3 months prior to screening; any contraindications to ascorbic
acid (nephrolithiasis, glucose-6-phosphate dehydrogenase deficiency or iron overload)
Interventions Ascorbic acid at a dose of 1.5 g per day as 3 x 0.5 g tablets (1 at breakfast and 2 at dinner)
(n = 138) or placebo tablets of identical appearance, taste and smell (n = 133)
Outcomes Primary outcome: CMTNS at 12 months after commencement of intervention
Secondary outcomes:
Muscle strength - MVIC using hand-held dynamometer for: hand-grip, 3-point pinch,
ankle dorsiflexion and plantarflexion
Pain - VAS
Fatigue - VAS
Activity - ONLS, 10 metre walk test, 9-hole peg test
Quality of life - Medical Outcomes SF-36
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Pareyson 2011 (Continued)
Funding This trial was supported by Telethon-UILDM (grant numbers GUP04002 and
GUP05007) and AIFA (Grant number FARM53APAH) in Italy, Muscular Dystrophy
Campaign (MDC RA3/736/1), CMTUK, UKMRC and NIHR BRC in the UK
Bracco SpA (Milan) provided ascorbic acid and placebo tablets
Declarations of interest One of the study authors (RACH)was a consultant forOctopharma, Baxter, Laboratoires
Francais de Fractionnement et desBiotechnologies (LFB) andNovartis.One study author
(ASo) was a board member of Novartis and received speaker’s honoraria from Sanofi-
Aventis
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation sequence was com-
puter-generated (pseudo-random number
generator) by an independent randomisa-
tion unit
Allocation concealment (selection bias) Low risk Randomisation sequence known only to
independent unit and the drug dispen-
sary for preparation of identically packaged
ascorbic acid and placebo tablets. Treat-
ment was allocated centrally by telephone
and stratified by centre and disease severity
(CMTNS≤ 10 versus > 10 orCMTES≤ 8
versus > 8) with a block size of 4 unknown
to the investigators in each centre
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants, treating physicians and physi-
cians assessing outcomes were blinded to
treatment allocation throughout study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data for 22 participants who were
lost to follow-up were imputed according
to Rubin’s multiple imputation approach.
Reasons for loss to follow-up were reported
in full with similar numbers in each group
for each reason: 13 participants had adverse
events (7 in ascorbic acid; 6 placebo), 6
withdrew their consent (3 in each group)
, 2 in the ascorbic acid group moved away
from the study area and 1 in the placebo
group left for personal reasons
A further 8 participants stopped treatment
but did attend follow-up so no imputed
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Pareyson 2011 (Continued)
data were used for these participants
Selective reporting (reporting bias) Low risk All stated primary and secondary outcomes
fully reported at 24 months
Other bias Low risk None
Incomplete outcome data (attrition bias). Summary assessment of risk of bias based on risk of bias associated with unclear description
of how missing data was managed in intention-to-treat analysis
CGI-S: Clinical Global Impression Severity Scale
CMT: Charcot-Marie-Tooth
CMTES: Charcot-Marie-Tooth Examination Score
CMTNS: Charcot-Marie-Tooth Neuropathy Score
EQHQ: Euroquol Health Questionnaire
FIS: Fatigue Impact Scale
FSS: Fatigue Severity Scale
GBS: Guillain-Barré syndrome
HADS: Hospital Anxiety and Depression Scale
MVIC: Maximal Voluntary Isometric Contractions
ODSS: Overall Disability Sum Score
ONLS: Overall Neuropathy Limitations Scale
RHS: Rotterdam Handicap Scale
Short Form 36 Health Survey
VAS: visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Burns 2009 RCT of ascorbic acid for CMT1A in children. Fatigue not used as an outcome
Carter 2006 Not a RCT - 4 single case series of fatigue reduction associated with modafinil treatment
Enderlin 2008 Not a RCT - observational study of sleep disturbance in multiple myeloma
NCT00484510 No relevant outcomes to be evaluated (only CMT neuropathy score and mRNA). Fatigue not used as an outcome
Verhamme 2009 RCT of ascorbic acid treatment for CMT1A in people under 25. Fatigue not used as an outcome
CMT: Charcot-Marie-Tooth; mRNA: messenger RNA; RCT: randomised controlled trial
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Characteristics of ongoing studies [ordered by study ID]
Attarian 2013
Trial name or title A phase II randomized, placebo-controlled multicenter clinical trial of three doses of PXT3003 in 80 adult
patients with CMT1A treated for 1 year
Methods Randomised double-blind placebo-controlled trial of 12 month intervention
Participants 80 participants between 18 and 65 years with DNA-proven CMT1A
Interventions 4-arm trial:
• 3 intervention arms of different dosages (low 1/100, intermediate 1/50, high 1/10) delivered as 5 ml
liquid doses twice daily of PXT3003 (a new low-dose combination of 3 already approved drugs (naclofen,
naltrexone and D-sorbitol)). In the highest dose, the active ingredients were 1/0 and 1/100 of the currently
used registered indication dosages.
• 5 ml liquid doses twice daily of placebo
Outcomes Primary objective was clinical and biological safety. Secondary objectives were to obtain preliminary data on
clinical and functional outcomes (including CMTNS, ONLS, 6MWT, 9HPT, VAS for fatigue and pain,
QMT - hand grip and ankle dorsiflexion and clinical global impression) and electrophysiological parameters
(including sensory and motor responses of median and ulnar nerves - NCV, DL and amplitude)
Starting date December 2010
Contact information S Attarian, Hopital La Timone
Notes Primary objective of determining clinical and biological safety achieved. Analyses of secondary outcomes
ongoing
NCT00541164
Trial name or title Effects of coenzyme Q10 on Charcot-Marie-Tooth disease
Methods Randomised, double-blind, cross-over trial with open-label follow-up study
Participants 18 to 75 years of age with CMT confirmed by medical record review. Regarding weakness, fatigue, and pain,
subjects must report experiencing maximum levels of 3.0 cm or more on the 10 cm visual analog scale (VAS)
for any 2 of the 3 symptoms over the past month
Interventions Coenzyme Q10, 600 mg/day (300 mg twice/day for 24 weeks) or chewable placebo twice/day for 24 weeks
followed by the alternative treatment in the cross-over period
Outcomes Primary: changes in weakness, fatigue and pain (60 weeks)
Secondary: improvements in quality of life (60 weeks); blood serum levels of the oxidised and reduced forms
of CoQ10 (60 weeks); liver function tests (visits 1, 6 and 12)
Starting date September 2007
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NCT00541164 (Continued)
Contact information Sharon Plank,MD. John PMurtha Neuroscience and Pain Institute, Johnstown, Pennsylvania, United States,
15904
Notes Study completion date January 2013
NCT02121678
Trial name or title Effects of coenzyme Q10 on Charcot-Marie-Tooth disease
Methods Randomised, parallel assignment, open-label
Participants Aged 18 to 80 years with definite or probable CIDP or definite or probable MMN of over 6months’ duration,
diagnosed according to EFNS/PNS criteria. On stable maintenance dose of intravenous immunoglobulin
Interventions Experimental: run-in - aerobic - resistance
• Week -12 to 0: no training
• Week 0 to 12: aerobic training (ergometer bicycle, twice weekly, increasing to 3 times weekly.
Participants to train at 60 - 75 % of maximal oxygen consumption (VO2-max) for 30 minutes per training
session)
• Week 12 to 24: resistance training (dumbbells: week 0 to 4: 70% to 80% of 1-repetition max (1-RM);
week 5 to 8: 75% to 86 % of 1-RM; week 9 to 12: 80% to 92% of 1-RM)
Experimental: run-in - resistance - aerobic
• Week -12 to 0: No training
• Week 0 to 12: Resistance training (dumbbells as above)
• Week 12 to 24: Aerobic training (ergometer bicycle as above)
For resistance training, participants train unilaterally, the opposite site serves as reference
• MMN participants train elbow and wrist (flexion/extension)
• CIDP participants train knee and elbow (flexion/extension)
Outcomes Primary (measured at -12, 0, 6, 12 weeks or -12, 0, 12, 18, 24 weeks):
• changes in isokinetic muscle strength
• changes in VO2-max
Secondary (measured at -12, 0, 6, 12 weeks or -12, 0, 12, 18, 24 weeks). Change in the following measures:
• Medical Research Council (MRC)
• change in ODSS
• change in 6-Minute Walk test
• change in Quality of Life measured by The Short Form (36) Health Survey (SF-36) questionnaire
• change in FSS
Starting date April 2014
Contact information Department of Neurology, Aarhus University Hospital. Contact: Henning Andersen, DMSc
Department of Neurology, Rigshospitalet, Copenhagen University Hospital: Contact: Ingelise Christiansen
Notes
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Ramdharry 2011
Trial name or title Strengthening hip flexors to improve walking distance in people with CMT disease
Methods Single-blinded, cross-over study. Duration of intervention 16 weeks
Participants 32 participants with CMT disease. Mean age 43.5 (SD 14.76) years with median CMTES of 10
Interventions 16-week home-based programme of training to increase hip flexor muscle strength
Outcomes Hip flexor muscle strength measured using fixed myometry at 4 angles (0, 20, 45 and 90 degrees). Secondary
outcomes of walking endurance, gait speed, exertion, fatigue and general activity not reported in abstract
Starting date Not reported
Contact information Ramdharry GM, MRC Centre for Neuromuscular Diseases, Department of Molecular Neurosciences, UCL
Institute of Neurology, London
Notes Study completed, awaiting authors’ reporting of outcomes in full publication prior to next update of systematic
review
6MWT: 6 metre walk test
9HPT: 9-hole peg test
CIDP: chronic inflammatory demyelinating neuropathy
CMT: Charcot-Marie-Tooth
DL: distal latency
EFNS/PNS: European Federation of Neurological Sciences/Peripheral Nerve Society
FSS: fatigue severity score
MMN: multifocal motor neuropathy
NCV: nerve conduction velocity
ODSS: Overall disability sum score
ONLS: Overall Neuropathy Limitations Scale
QMT: quantitative muscle testing
PMP22 mRNA: peripheral myelin protein 22 (PMP22) messenger RNA
PXT3003: a low-dose combination of naclofen, naltrexone and D-sorbitol
VAS: visual analogue scale
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D A T A A N D A N A L Y S E S
Comparison 1. Ascorbic acid versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in fatigue > 12 weeks
after commencement of
intervention (measured at 12
to 24 months) (VAS 0 - 10 or 0
- 100)
2 404 Std. Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.32, 0.08]
2 Change in 10 m timed walk >
12 weeks after commencement
of the intervention (measured
at 12 to 24 months)
2 406 Mean Difference (IV, Fixed, 95% CI) -0.39 [-1.04, 0.26]
3 Change in speed of completion
of 9 hole peg test > 12 weeks
after commencement of
intervention (measured at 24
months)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4 Change in physical function
score of SF-36 > 12 weeks
after commencement of the
intervention (measured at 12
to 24 months)
2 400 Std. Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.12, 0.28]
5 Change in mental function
score of SF-36 > 12 weeks
after commencement of the
intervention (measured at 12
months)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6 Serious adverse events 2 450 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.39, 1.27]
A D D I T I O N A L T A B L E S
Table 1. Data and analysis: amantadine versus placebo
Outcome Studies Participants Statistical method Effect estimate
Change in participation
(using the Rotterdam
Handicap Scale) > 12
weeks after commence-
ment of intervention
1 (cross-over) 74 Mean difference (IV, Fixed, 95%
CI)
0.31 [-0.09 to 0.72]
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WH A T ’ S N E W
Last assessed as up-to-date: 5 November 2013.
Date Event Description
18 December 2014 Amended Correction to plain language title
C O N T R I B U T I O N S O F A U T H O R S
CMW, MG and RCS screened lists of abstracts and titles from electronic and manual searches, CMW and RCS extracted data
from included study, CMW prepared first draft of the review and the other authors (PAvD, MPJG and RCS) reviewed the draft.
CMW incorporated comments after discussion, where appropriate and the final draft was returned to all authors for approval prior to
submission.
D E C L A R A T I O N S O F I N T E R E S T
One author (CW) is currently conducting a single-blind randomised controlled trial of tailored home exercise for people with inflam-
matory neuropathy (Home exercise for Inflammatory Neuropathy Trial - HINT). The trial is funded by the Guillain-Barré syndrome
support group UK (GBSSG). CW is on the Medical Advisory Board of the GBSSG UK. She has no known conflicts of interest.
Pieter A van Doorn (PAvD) and his institution have received consultancy fees from Talecris and CSL Behring for membership of the
Scientific board of the ICE trial in CIDP and a scientific board on IVIg in chronic polyneuropathy. PAvD’s department has received
research grants from Baxter, Sanquin and Talecris: 1. A grant to conduct a RCT comparing IVIg versus IVIg and steroids in Guillain-
Barré syndrome; 2. A grant to conduct a RCT investigating the effect of a second course of IVIg (SID-trial) in Guillain-Barré syndrome
patients with a poor prognosis; 3. A grant to conduct a prospective international study on the effect of a second course of IVIg in
Guillain-Barré syndrome patients with a poor prognosis. MPG and PAvD have co-ordinated or conducted one of the trials that was
eligible for inclusion in the review (Garssen 2006).
Marcel P Garssen has no known financial conflicts of interest.
Rachel Stockley has no known conflicts of interest.
S O U R C E S O F S U P P O R T
Internal sources
• Kings College London, UK.
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External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Our protocol stated that we would consider trials for inclusion where interventions for fatigue formed part of a multidimensional
programme; however, we removed this inclusion criterion.
We removed PEDRO from the list of resources searched.
Use of funnel plots was not appropriate given the small number of studies included.
We revised the potential subgroup analyses, removing age. We also added a definition of ’significant weakness’.
We revised the section Dealing with missing data, which originally stated ’If participant drop out leads to missing data, we shall
conduct an intention-to-treat analysis. We shall contact trial authors or sponsors of studies to provide missing statistics such as standard
deviations. For dichotomous outcomes, we shall regard participants with missing outcome data as treatment failures and include these
in the analysis. For continuous outcomes, we shall carry forward the last recorded value for participants with missing outcome data.’
The section was revised since two of the included studies Micallef 2009; Pareyson 2011 undertook an intention-to-treat analysis where
missing data were reported. The third study (Garssen 2006) was a cross-over trial that reported reasons for withdrawing participants
with missing data effectively, and where data were analysed for the review as the number of participants responding favourably to the
intervention versus placebo in either period; imputation of data was not appropriate,
We did an additional search of clinical trials registries, for ongoing trials.
We included more detail in our adverse events outcome, subdividing it into “any adverse events, adverse events which lead to discontin-
uation of treatment and serious adverse events, which are those which are fatal, life-threatening, or require prolonged hospitalisation.”
I N D E X T E R M S
Medical Subject Headings (MeSH)
Amantadine [adverse effects; ∗therapeutic use]; Ascorbic Acid [adverse effects; ∗therapeutic use]; Charcot-Marie-Tooth Disease
[∗complications]; Fatigue [etiology; ∗therapy]; Guillain-Barre Syndrome [∗complications]; Peripheral Nervous System Diseases [com-
plications]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Child; Humans
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